Monday, March 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

Study Reveals Level of Dengue Virus Necessary for Transmission

by Global Biodefense Staff
May 14, 2013

Dengue virus (DENV)Researchers have identified the dose of dengue virus in human blood that is required to infect mosquitoes when they bite. Mosquitoes are essential for transmitting the virus between people so the findings have important implications for understanding how to slow the spread of the disease. 

By defining the threshold of the amount of virus needed for transmission, the research also provides a target that experimental dengue vaccines and drugs must prevent the virus from reaching in order to be successful at preventing the spread of disease during natural infection.

Dengue is a viral infection that is transmitted between humans by mosquitoes. In most people it causes flu-like symptoms but in a small proportion of cases the disease can become life-threatening. Recent estimates indicate that there are 390 million infections of dengue across the globe each year and with no vaccine or specific treatment available, current measures to prevent the spread of disease are focused on controlling the mosquito vector. 

In research funded by the Wellcome Trust, scientists and doctors at the Oxford University Clinical Research Unit at the Hospital for Tropical Diseases in Vietnam studied the factors that influence the transmission of dengue viruses from dengue patients to the mosquitoes that feed on them. Their findings reveal that mosquitoes that feed on dengue patients with very high levels of virus in their blood are more likely to be infectious to other humans two weeks later.

“Our findings suggest that focused public health intervention strategies to prevent transmission from these ‘high risk’ spreaders of the virus could have a major impact in slowing the spread of disease,” explains Professor Cameron Simmons, a Wellcome Trust Senior Fellow at the Oxford University Clinical Research Unit in Vietnam. 

Although the levels of virus in patients who had been hospitalized by the disease were much higher, the majority of patients with mild symptoms who were treated at outpatient centers also had enough virus in their blood to support transmission. 

“At the moment, dengue surveillance systems typically only count hospitalized patients but our findings confirm that less serious cases represent an equally important source of virus infection. Since these cases often remain in the community for the duration of their illness, it’s important that we explore ways to prevent such patients from providing a source of further virus transmission,” added Professor Simmons.

The researchers hope that understanding the level of virus needed for transmission of infection will provide a useful reference point for the development of experimental drugs and vaccines and could be used to inform the endpoints for clinical trials evaluating such interventions.

Source: Wellcome Trust

Tags: DengueMosquito-Borne

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
NIH Grant Awarded to Study Evolution of Lyme Disease Bacteria in Deer Ticks
Pathogens

NIH Grant Awarded to Study Evolution of Lyme Disease Bacteria in Deer Ticks

December 7, 2022
Bat Virus Receptor Studies Vital to Predict Spillover Risk
Pathogens

Bat Virus Receptor Studies Vital to Predict Spillover Risk

December 7, 2022
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC